Histone deacetylases and Cancer
The below-listed papers have been reviewed and their summary is illustrated to construct the essence of histone deacetylases in cancer progression. HDAC inhibitor as novel anticancer therapeutics. Many of the drugs inhibiting HDACs are in clinical phase-2 and phase-3 trials while one drug for T-Cell lymphoma has been proven by the FDA. It affects DNA histone interaction at the N-terminal of core histone-protein and histone-histone interaction. Its interactive non-histone protein partners are tubulin, Hsp90, beta-catenin, etc. Its high expression leads to cancer, as it suppresses p53 which is a tumor suppressor and due to translocation, HDAC is fused with other proteins (repressor or activator) which recruit it to the gene promoter site. HDAC is divided into four classes (Class 1, Class 2(a, b), Class 3, and Class 4) and 2 families (based on homology) which are the Rdp3/Hda1 family and Sirtuin family (NAD+ Dependent Sir2). Family members show sequence similarity in the ...